Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons

Diabetes, Obesity and Metabolism

Volumn 20, Issue 3, 2018, Pages 508-519

  Dalsgaard, Niels B ^a   Vilsbøll, Tina ^a,b   Knop, Filip K ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cardiovascular disease; GLP 1 analogue; incretin therapy; randomized trial

Indexed keywords

ALBIGLUTIDE; C REACTIVE PROTEIN; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; LIXISENATIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEMAGLUTIDE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN;

BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART RATE; HUMAN; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SYSTOLIC BLOOD PRESSURE; AGONISTS; BLOOD PRESSURE; BODY WEIGHT LOSS; DIABETIC ANGIOPATHY; LIPID METABOLISM; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

BIOMARKERS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCATED HEMOGLOBIN A; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WEIGHT LOSS;

EID: 85033238911     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13128     Document Type: Review

References (75)

1. International Diabetes Foundation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium: IDF; 2015. www.diabetesatlas.org. Accessed February 15, 2017.
2. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2)):S49–S73.
3. Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016, 2016;23(11):Np1-np96.
4. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50(9):823–830.
5. Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167(16):1720–1728.
6. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–615.
7. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26(10):967–974.
8. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
9. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772.
10. International Diabetes Foundation. IDF global guideline for type 2 diabetes, 2012. http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf. Accessed February 16, 2017.
11. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
12. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary. Endocr Pract. 2016;22(1):84–113.
13. Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25(5):407–414.
14. Amylin Pharmaceuticals. Byetta® (exenatide) injection, prescribing information, 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf. Accessed February 16, 2017.
15. AstraZeneca AB. Byetta summary of product characteristics, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf. Accessed February 22, 2017.
16. Amylin Pharmaceuticals. Bydureon™ (exenatide extended-release for injectable suspension), prescribing information, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200s000lbl.pdf. Accessed February 16, 2017.
17. AstraZeneca AB. Bydureon summary of product characteristics, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf. Accessed February 22, 2017.
18. Sanofi-Aventis US. Adlyxin (lixisenatide), prescribing information, 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf. Accessed February 16, 2017.
19. Sanofi-Aventis. Lyxumia summary of product characteristics, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf. Accessed February 22, 2017.
20. Novo Nordisk A/S. Victoza® (liraglutide injection), prescribing information, 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf. Accessed February 16, 2017.
21. Novo Nordisk A/S. Victoza summary of product characteristics, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf. Accessed February 22, 2017.
22. GlaxoSmithKline. Tanzeum (albiglutide), prescribing information, 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf. Accessed February 16, 2017.
23. GlaxoSmithKline. Eperzan summary of product characteristics, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002735/WC500165117.pdf. Accessed February 22, 2017.
24. Eli Lilly and Company. Trulicity (dulaglutide), prescribing information, 2017. http://pi.lilly.com/us/trulicity-uspi.pdf. Accessed February 16, 2017.
25. Eli Lilly. Trulicity summary of product characteristics, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf. Accessed Febuary 22, 2017.
26. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260.
27. Henry RR, Schwartz B, Kjems L, Huang H, Baron M. ITCA-650 improves glycemic control and reduces the need to advance antidiabetes therapy. Presented at the American Diabetes Association 2017; June 9–13, 2017; San Diego, CA; Poster 1078.
28. Rosenstock J, Buse JB, Azeem R, Kjems L, Baron MA. Clinical impact of ITCA 650 in type 2 diabetes: a randomized, double-blind, placebo-controlled, 39-week trial. Diabetes. 2015;64(suppl 1):A73.
29. Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014;28(3):393–398.
30. Davies M, Thiman M, Kugler A. Efpeglenatide: a once monthly GLP-1 RA in the pipeline. Austin J Endocrinol Diabetes. 2016;3(4):1053.
31. US Food and Drug Administration. Guidance for industry. Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed March 16, 2017.
32. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
33. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
34. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
35. Intarcia Therapeutics. Press Release: Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO Trial for ITCA 650, 2016. https://www.intarcia.com/media/press-releases/2016-may-6-cardiovascular-safety.html. Accessed April 25, 2017.
36. AstraZeneca AB. Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk, 2017. https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html. Accessed June 5, 2017.
37. Eli Lilly and Company. Researching cardiovascular events with a weekly incretin in diabetes (REWIND), 2017. https://clinicaltrials.gov/ct2/show/NCT01394952?term=NCT01394952&rank=1. Accessed June 22, 2017.
38. GlaxoSmithKline. Effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in subjects with type 2 diabetes mellitus, 2017. https://clinicaltrials.gov/ct2/show/NCT02465515?term=NCT02465515&rank=1. Accessed June 22, 2017.
39. Novo Nordisk A/S. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes (PIONEER 6), 2017. https://clinicaltrials.gov/ct2/show/NCT02692716. Accessed March 28, 2017.
40. Dalsgaard NB, Bronden A, Vilsboll T, Knop FK. Cardiovascular safety and benefits of GLP-1 receptor agonists. Expert Opin Drug Saf. 2017;16(3):351–363.
41. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742.
42. Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, Semaglutide, compared with placebo and open-label Liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39(2):231–241.
43. Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B. Once-daily Liraglutide versus Lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial. Diabetes Care. 2016;39(9):1501–1509.
44. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32(10):1880–1886.
45. Ahmann A, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). Diabetologia. 2016;59(suppl 1):S76. Abstract 147.
46. Nakatani Y, Kawabe A, Matsumura M, et al. Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using Holter electrocardiography and power Spectrum analysis of heart rate variability. Diabetes Care. 2016;39(2):e22–e23.
47. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250.
48. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.
49. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310.
50. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–124.
51. Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013;36(10):2945–2951.
52. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289–297.
53. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159–2167.
54. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–1357.
55. Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Mery A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013;15(7):642–649.
56. Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of Lixisenatide and Liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin Glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263–1273.
57. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17(10):974–983.
58. Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016;18(3):249–257.
59. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224–2260.
60. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–1252.
61. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–1320.
62. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med. 2013;173(8):664–671.
63. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
64. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565–1576.
65. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
66. Ussher JR, Baggio LL, Campbell JE, et al. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab. 2014;3(5):507–517.
67. Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009;9(Suppl 1):S3.
68. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.
69. Punjabi M, Arnold M, Ruttimann E, et al. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Endocrinology. 2014;155(5):1690–1699.
70. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–4488.
71. National Institute for Health and Care Excellence, Internal Clinical Guidelines Team. Type 2 diabetes in adults: management, 2015. https://www.nice.org.uk/guidance/ng28. Accessed September 6, 2017.
72. Wang A, Chen S, Wang C, et al. Resting heart rate and risk of cardiovascular diseases and all-cause death: the Kailuan study. PLoS One. 2014;9(10):e110985.
73. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–1401.
74. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–1909.
75. Persu A, Jin Y, Fadl Elmula FE, Jacobs L, Renkin J, Kjeldsen S. Renal denervation after Symplicity HTN-3: an update. Curr Hypertens Rep. 2014;16(8):460.